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Summary.-Serum inhibition of autochthonous lymphocyte cytotoxicity for tumour
cells has been studied in 112 cases of colonic carcinoma. Addition of patient's
serum to the lymphocyte tumour cell reaction mixture resulted in decreased cyto-
toxic reactivity of lymphocytes from 8 of 39 cytotoxic positive cases. It was also
shown that sera could inhibit if separately preincubated with the lymphocytes (4
cases) or the target cells (2 cases). A tumour antigen preparation inhibited only
when incubated with the lymphocytes. Inhibition by serum or antigen appeared
to be specific for colon carcinoma. Four cases were specially studied to determine
the mode of lymphocyte killing of tumour cells: in 3 it was mediated largely if not
entirely by T lymphocytes, and in the fourth by both T and non-T cells. The findings
support the view that T lymphocytes lose their anti-tumour reactivity in vivo in the
presence of circulating antigen or antigen-antibody complexes such as would occur
with progressive tumour growth.
IN PREVIOUS reports oflymphocyte anergy
in patients with carcinoma (Nind et al.,
1973), it was speculated that the observed
in vitro inactivity of the local lymphocyte
populations might be due to in vivo
inactivation of specific effector cells by
free tumour antigen or complexes of
tumour antigen with tumour directed
antibody. This would explain the de-
crease in leucocyte cytotoxicity and the
increase in serum inhibitory effect that
follows progressive growth or regrowth
of tumour (Nairn et al., 1974). Study
of the phenomenon of inhibition of leuco-
cyte cytotoxicity has hitherto been ham-
pered by ignorance of the particular
effector cell type when testing in vitro.
We have now obtained inhibition of
cytotoxicity by pretreatment of effector
or target cell populations with sera of
colon carcinoma patients and have also
prepared a tumour antigen extract capable
of inactivating the effector cells. The
reactions in limited cross-reactivity tests
with other tumour systems appeared to
be specific for colon carcinoma. Frac-
tionation studies in 4 cases showed the
lymphocyte class cytotoxic for the colonic
carcinoma cells to be predominantly
T cell.
MATERIALS AND METHODS
Specimen and blood collection were as
described previously (Nairn et al., 1971;
Nind et al., 1973). Tumours, lymph nodes
adjacent to the tumour, and in 2 cases
spleen removed at operation, were teased
gently into culture medium 199 containing
10% foetal calf serum (hereafter referred to
as the culture medium). The resultant
suspensions (tumour cells washed twice,
spleen and lymph node cells washed 7
times with culture medium) were used
fresh for immediate testing and any residue
was stored with 10% dimethylsulphoxide in
liquid nitrogen for later use. Lymphocytes
were obtainedfrom heparinized blood samples
by sedimentation of the erythrocytes at
37°C and washing the leucocyte-rich super-
natant plasma through a 2 cm glass wool
column with culture medium. The lympho-
cyte eluate, which was contaminated by
less than 10% granulocytes, was washed
7 times with culture medium before use.INHIBITION OF LYMPHOCYTE CYTOTOXICITY IN HUMAN COLON CARCINOMA 621
Serum obtained from clotted blood samples
from each patient was complement inactiv-
ated at 56°C for 30 min.
Lymphocyte cytotoxicity testing.-This was
performed quantitatively in Falcon 3034
microtest plates by a modification of the
method of Takasugi and Klein (1970) (Pihl,
Nind and Nairn, 1974). Tumour cell suspen-
sions, adjusted to 105 cells/ml in culture
medium were micropipetted in 10 ,ul volumes
into each well. Plates were incubated for
24 h at 37°C in a moist atmosphere of 5%
CO2 in air. They were then washed 3 times
with culture medium to remove non-adhered
tumour cells. Those remaining in each well
were counted and lymphocytes were added
at a ratio of 200 to 1 tumour cell, in rows
of 5 or 6 replicate wells for each experiment.
The culture plate was reincubated for a
further 48 h, washed gently 3 times with
physiological saline at 37°C, and the remain-
ing adherent cells were fixed with methanol
for 10 min and counted under water using
an inverted phase-contrast microscope. Test
blood lymphocytes were accompanied by a
row of homologous control blood lympho-
cytes obtained from 1 of 20 normal healthy
adults of either sex. Control splenocytes
were from a splenectomized patient who
had a small leiomyosarcoma of the stomach.
Cytotoxicity was expressed as
nC - nT 100
where nC is the mean number of tumour
cells remaining adherent in the control wells
and nT the mean number remaining in the
test wells. Student's t test was performed
for each experiment and a difference between
cytotoxicity means at the P < 0 05 level
wras regarded as significant.
Serum inhibition of lymphocyte cyto-
toxicity.-This was tested in 112 cases
(39 of which were positive for autochthonous
lymphocyte cytotoxicity by blood, lymph
node or spleen) by the incorporation of 500
patient's serum in the lymphocyte suspension
immediately before adding to the target
cells. As controls, 500 normal group AB
serum was added to patient's lymphocytes,
and each serum was tested on homologous
normal lymphocytes. Inhibition was ex-
pressed as a percentage according to the
formula
CAB - CP 100
CAB
where CAB was the cytotoxicity of the
patient's lymphocytes with normal group AB
serum and Cp their cytotoxicity with the
patient's serum. Student's t test was used
to compare the cell counts with test and
control sera and a difference between means
at the P < 0-05 level was regarded as
significant inhibition.
Preincubation oflymphocytes with serum.-
Three sera (Cases 1, 2, 4) with strong autoch-
thonous inhibition by the routine test were
also tested in homologous colonic carcinoma/
lymphocyte systems (Cases 1, 3, 6, 32, 37)
(see Table I). One or 2 of these 3 sera were
preincubated with the lymphocytes of each
of the 5 cases before addition to target
tumour cells. This was performed by adding
to 5 ,ll oftest serum in a polystyrene Durham
tube, 0-1 ml of lymphocyte suspension,
usually containing 2 x 10f6/ml, adjusted
where necessary to provide the usual ratio of
lymphocytes to tumour cells of 200: 1.
After mixing, the tube was incubated at
37°C in a moist atmosphere of 5% CO2
in air for 45 min. The cells were then
washed twice with culture medium by
centrifugation at 500 gmax for 5 min and
resuspended in 0-1 ml of culture medium;
10 ,ul aliquots were added to target cell
wells for cytotoxicity testing in the usual
way. Inhibition was detetmined using simi-
lar cont-rols and the same calculation pro-
cedure as for the routine serum inhibition
test.
Specifiicity of serum inhibition.-Cross-
reactive inhibition tests by serum from
colonic carcinoma patients were performed
with cytotoxic lymphocytes and target cells
from different colonic carcinomata, carcino-
mata of the stomach and malignant melano-
mata. By the routine technique, inhibitory
sera from up to 3 colonic carcinomata were
tested by addition to the lymphocyte
tumour systems of 3 other homologous
colonic carcinomata, 1 gastric carcinoma and
3 melanomata. Autochthonous inhibitory
sera from 1 gastric carcinoma and 2 melano-
mata were examined in cytotoxicity tests of 2
autochthonous lymphocyte positive colonic
carcinoma cases. The specificity of inhibi-
tory sera preincubated with lymphocytes
was examined for up to 3 colonic carcinoma
sera tested with the lymphocytes of each
of 5 homologous colonic carcinomata, 2
gastric carcinomata and 2 melanomata
reacted against their autochthonous tumours.A. NTND, N. MATTHEWS, E. PIHL, J. ROLLAND AND R. NAIRN
Autochthonous inhibitory sera from 1 gastric
carcinoma and 2 melanoma patients were pre-
incubated with the lymphocytes of each of
3 coloniccarcinoma casesandthe lymphocytes
then tested against their respective tumours.
Preincubation of lymphocytes with antigen.
-Homogenized and de-fatted tissue from
a colonic carcinoma (Case 1) was acid
extracted by the method of Dickinson,
Caspary and Field (1973), dialysed against
water and freeze-dried for use as required.
A similar extract was prepared from 10
pooled normal colon mucosas. Any inhibi-
tory, activity of the preparations was deter-
mined by preincubating at concentrations
of 5, 5 x 10-1, 5 X 10-2, 5 x 10-3 and
5 x 10-4 /g dry weight of antigen per ml
with the splenocytes from Case 1, which
were then washed twice and tested for
cytotoxicity by adding to Case 1 tumour
cells in microculture plates. In control
cytotoxicity experiments, equivalent con-
centrations of either antigen were pre-
incubated with homologous normal lympho-
cytes or splenocytes. Specificity of inhibi-
tion by the tumour antigen was investigated
by preincubating the extract at the same
concentrations with lymphocytes from one
case each of carcinoma of the stomach and
melanoma before they were reacted with
their respective tumour cells. In further
experiments lymphocytes from 4 other
colonic carcinoma cases, one other gastric
carcinoma and one other melanoma were
pretreated with 0 5 ,ug/ml of either antigen.
Preincubation of lymphocytes with antigen
plus serum.-To determine if serum and
antigen effects were additive, Case 1 serum,
which inhibited 4 of 5 colonic carcinoma
tests, was combined with 0 5 ,ug/ml of the
tumour antigen extract, which gave alone
about 50% inhibition. The mixture was
preincubated with the lymphocytes of the
same 5 cases, which were then tested for
cytotoxicity against their respective targets
and compared with lymphocytes pretreated
with serum or tumour antigen alone.
Preincubation of target tumour cells with
antigen and serum.-The tumour cells of 2
cases (Case 1, 6) were preincubated with
tumour antigen, inhibitory serum or both
together. Replicate tumour cell microcul-
tures were incubated at 37°C for 45 min in
a moist atmosphere of 5% CO2 in air with
0-01 ml aliquots of (a) 5% inhibitory serum.
(b) 0-5 ,tg/ml of tumour antigen or (c) a
mixture of both, each at the same concen-
tration as in (a) or (b). The preparations
were then washed twice with culture medium
and the relevant lymphocytes were added
in the usual ratio of 200: 1 tumour cell.
Comparison was made with tests against
untreated target cells.
Fractionation of lymphocyte populations
by rosette formation.-Human lymphocytes
forming rosettes with sheep erythrocytes
have the characteristics of T cells (Coombs et
al., 1970; Jondal, Holm and Wigzell, 1972).
Lymphocyte preparations purified by Hy-
paque-Ficol sedimentation were incubated
with sheep erythrocytes for 1 h at 37°C
and again centrifuged in Hypaque-Ficol
(Wybran et al., 1974). The non-rosette
forming cells at the interface and the rosetted
cells in the pellet were collected carefully
and counted. The cells were washed twice
and resuspended in culture medium at the
appropriate concentration for cytotoxicity
testing (usually 2 x 106/ml). Sheep ery-
throcytes were added to the unfractionated
and non-rosette forming populations to
make the cell density the same as in the
rosette forming fraction. Aliquots of either
fraction and of the unfractionated cells were
added to microcultures of target cells for
cytotoxicity testing in a minimum of 10
replicate wells to give at least 18 degrees of
freedom for each test of significance. In 2
experiments, normal homologous lymphocyte
populations (one spleen, one blood) were
fractionated simultaneously with the test
lymphocytes to provide cytotoxicity con-
trols. In another 3 experiments, where this
was not done, the test preparation was
compared with an unfractionated control.
Preliminary experiments with normal blood
lymphocytes showed that the fractionation
did not confer cytotoxicity on non-cytotoxic
unfractionated cells.
RESULTS
Serum inhibition of lymphocyte cytotoxicity
Eight of the 39 (21%) lymphocyte
cytotoxic cases showed significant reduc-
tion of cytotoxicity by their serum added
to the lymphocyte/tumour cell mixture
(Table I). Three of the inhibitory sera
tested (Cases 1, 2, 4) produced significant
inhibition with 3 other colonic carcinoma
systems but only slight inhibition in
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TABLE I.-Results ofSerum Inhibition Tests in Lymphocyte Cytotoxic-positive
Cases of Colonic Carcinoma
Tumour cell no./well
Patient's lymphocytes
Patient's Normal
serum serum
20±2 15±3
17±6 6±2
31±2 23±2
29±4 21±4
21±2 18±2
26±5 24±5
35±3 23±2
18±2 17±4
19±2 15±2
21±2 15±2
21±5 17±4
25±6 25±3
21±3 20±2
13±2 15±2
27±3 26±3
23±3 21±3
28±4 25±5
8±1 7±2
47±5 44±5
4±1 4±1
39±8 45±7
27±5 30±2
38±7 48±9
10±3 11±5
12±3 13±3
11±2 15±5
4±1 6±2
14±4 19±4
9±2 11±3
16±2 20±5
15±9 18±9
18±6 21±2
12±2 12±1
20±3 23±2
33±15 34±7
18±2 19±2
20±4 22±3
10±3 11±3
12±3 12±5
Control lymphocytes
Patient's Normal
serum serum
19±2 22±3
14±6 15±4
30±4 29±3
31±3 30±4
23±2 23±2
29±6 31±8
53±4 51±9
22±1 24±2
25±4 26±5
34±1 35±9
30±6 28±3
30±3 32±1
25±3 25±2
17±3 21±5
40+2 41±1
45±2 47±2
67±5 68±7
36±2 38±3
107±7 105±13
28±4 27±6
62±9 53±12
40±6 45±5
63±5 65±3
45±5 44±4
20±2 20±3
43±2 42±4
37±4 37±3
32±8 31±4
20+2 20±2
30±3 30±3
28±5 30±5
33±2 33±5
23±3 23±2
29±3 28±2
61±8 60±4
25±3 24±3
33±2 32±3
23±3 25±2
20±1 20±2
o/o
Inhibition
100
100
100
80
59
57
38
38
36
33
23
22
20
17
11
11
8
5
3
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Degrees of
freedom
8
8
8
10
8
8
8
10
8
8
8
8
10
10
8
10
10
10
10
10
18
10
10
9
8
10
10
9
10
10
10
10
10
10
10
10
10
8
8
*0.05>P>0.01. **0.01>P>0.001. ***P<0.001.
t Tested by splenocytes with homologous splenocytes as control.
t Tested by lymph node lymphocytes with homologous blood lymphocytes as control.
with blood lymphocytes.
carcinoma of the stomach and no inhibi- trations of the colonic carcin
tion in 3 melanomata. Autochthonous resulted in a gradual decre
inhibitory sera from 2 patients with toxicity (Figure). There wa
melanoma and 1 with carcinoma of the cant inhibition by normal cc
stomach were not inhibitory when added The colonic tumour antigen
to 2 colonic carcinoma cytotoxic systems concentrations did not inhibit
(Cases 1 and 15). cytes of a patient with c
stomach (Case 40) or melanor
Preincubation of lymphocytes with antigen, Pretreatment with 05 ,uE
serum or both together carcinoma antigen reduced
Pretreatment of the reactive spleno- by lymphocytes of 3 (Case.
cytes from Case 1 with increasing concen- of 4 cases of colonic car
t
value
3-1*
3-9**
6-3***
3 -5**
2-4*
0-6
7 -4***
0 4
3-2*
4- 7**
1 -4
0
0 7
1 -7
0*5
1-1
1*1
1-1
1.0
0
1 -8
1 -4
2-1
0 4
0*5
1 -8
2 -2
1-5
1 -4
1 -8
0-6
1 -2
0
2 0
0-1
0 9
1*0
0*5
0
Case
No.
1 (73/142)
2 (73/115)
3 (74/113)
4 (73/163)
5 (74/87)
6 (74/139)t
7 (73/83)$
8 (74/12)
9 (74/120)t
10 (74/102)
11 (74/121)
12 (74/81)t
13 (74/137)
14 (74/54)
15 (74/77)
16 (73/130)
17 (73/70)
18 (74/48)
19 (74/50)
20 (73/134)
21 (73/53)
22 (73/72)
23 (73/92)
24 (73/96)
25 (73/106)
26 (73/138)
27 (73/141)
28 (74/3)
29 (74/13)
30 (74/26)
31 (74/32)
32 (74/43)
33 (74/64)
34 (74/70)
35 (74/92)
36 (74/94)
37 (74/104)
38 (74/112)t
39 (74/132)
All other tests
oma antigen
,ase in cyto-
is no signifi-
Dlon antigen.
at the same
the lympho-
arcinoma of
ma (Case 42).
;/ml colonic
cytotoxicity
s 3, 32, 37)
-cinoma (seeA. NIND, N. MATTHEWS, E. PIHL, J. ROLLAND AND R. NAIRN
----Colon carcinoma (Case 1) + Tumour Antigen
._
0
._
x
o
Io-0
itigen
pg Antigen / ml
FIG.-Effect on autochthonous lymphocyte anti-tumour cytotoxicity of preincubating lymphocytes with
preparations of colonic carcinoma or normal colon at different concentrations.
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TABLE IL-Effect ofPreincubation of Cytotoxic Lymphocytes with Inhibitor!y
Serum and Antigen Preparations
% Inhibition wvith
Tumour antigen
Normal colon
antigen
5 % serum of Case I
Lyinphocytest Tumour -,- 5%serum Tumour ant
Case no. Case no. 5 /zg/ml 0 5 jig/ml 5 /pg/ml 0 5 ,g/ml of Case 1 0 5 ug/rm
Ca Colonl
1 1 99** 54** 27 24 95+ 0
32 6 .. 48* .. 0 48* 0
6 6 0 0 0 0 81** 75*
37 37 100** 60* 0 0 46* 100**
3 :3 100** 100* 24 6 30*
C(a Stomat(tch
40 40 0 10 0 0 24
41 41 .. 0 .. 0 0 0
MVela nboma
42 42 9 0 8 0 23
43 43 0 .. 0 .. 5
t Untreated lymphocyte cytotoxicity values ranged from 25% to 44% an(i all were significant.
Not (lone.
*0 05 > P > 0-01; ** 0-01 > P > 0-001.
;igen
II
Table II). Case 6 showed no inhibition
nor did 1 carcinoma of stomach (Case 41)
and 1 melanoma (Case 43). The same
concentration of normal colon extract
did not inhibit any of the 5 colonic
carcinoma lymphocyte preparations.
Preincubation of lymphocytes with
serum resulted in 4 of the 5 colonic
carcinoma cases tested showing reduction
of lymphocyte cytotoxicity with at least
1 of the 3 sera. The results obtained
with the serum of Case 1 are summarized
in Table II. Case 3, which showed no
inhibition by serum from Case 1, was not
tested with the other 2 sera. The serum
from Case 1 did not significantly inhibit
when preincubated with lymphocytes in
2 positive gastric carcinoma systems
(Cases 40, 41) and 2 melanomata (Cases
42, 43). Autochthonous inhibitory sera,
detected by the same technique, from
1 gastric carcinoma case and 2 melano-
mata did not interfere with the lympho-
cyte reactivity of any of 3 colon carcino-
mata (Cases 1, 32, 36).
The results of preincubating with the
mixture of antigen plus serum, sum-
marized also in Table II, were not uniform
in the 5 cases studied. Where preincuba-
tion with either the serum or antigen
separately caused inhibition, in Case 37,
the mixture gave increased inhibition
while in Cases 1 and 32 there was no
change. Where only antigen reduced
cytotoxicity (Case 3), addition of the
inhibitory sera abrogated this effect.
There was no change in serum inhibition
in Case 6 by adding tumour antigen.
Additional data from separate experi-
ments (Table III) make comparisons
between lymphocyt2 and target cell pre-
incubations. The difference in the per-
centage cytotoxicity of similar prepara-
tions in Tables II and III are within the
limits ofexperimental variation.
Preincubation of target tumour cells with
antigen, serum or both together
The colonic carcinoma antigen pre-
paration, as might be expected, had no
effect on the tumour cells (Table III).
Inhibitory serum blocked tumour cells
as targets whether tested against auto-
chthonous or homologous lymphocytes.
Combination of serum with the antigen
preparation studied in Cases 1 and 6
resulted in abrogation of serum blocking.A. NIND, N. MATTHEWS, E. PIHL, J. ROLLAND AND R. NAIRN
TABLE III.-Comparison ofEffect ofPreincubation ofTarget Tumour Cells and
Cytotoxic Lymphocytes with Antigen and Inhibitory Serum
% Blocking or inhibition
\~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Tumour antigent
preincubated with
Tumour, 1 A
Case no. Lymphocytes Tumour
1 96** 6
6 40** 9
1 29 0
6 0 0
Serum:
preincubated with
Lymphocytes Tu-mour
100** 30**
54* * 60* *
79* * 0
81** 49**
Tumour antigent
+ serumt
preincubated with
Lymphocytes Tumour
18 0
0 5
61*** 0
75*** 23
* Untreated lymphocyte cytotoxicity values rangedfrom 46% to 49 % for Case 1 and 35% to 38 %forCase 6;
all were significant.
t 0 5 ,ig/ml.
1 5 % serum from Case 1.
** 0-05 > P > 0-01; *** 0-01 > P > 0-001.
Fractionation of lymphocyte populations by
rosette formation
The results of the 5 cytotoxic positive
cases studied by these procedures are
summarized in Table IV. The rosette-
rich fraction of 4 of 5 cases showed
cytotoxicity to the tumour, while the
non-rosette forming fraction was cytotoxic
in only one of the 5 (Case 39); in Case 37,
the cytotoxicity was lost by fractionation.
This last was possibly due to a require-
ment for co-operation by both cell classes.
None of the control homologous lympho-
cyte fractions showed cytotoxicity. Cases
1 and 6 were tested with frozen-thawed
splenocyte preparations, and because the
Hypaque-Ficol centrifugation tended to
concentrate dead cells in the pellet, the
rosette counts are lower than would
otherwise be expected. However, this
does not invalidate the results because
neither case showed cytotoxicity in the
non-rosette forming fraction in which the
proportion of viable cells had been
selectively increased.
DISCUSSION
Investigations in 5 cases suggest that
human in vitro anti-colon carcinoma
lymphocyte cytotoxicity is mostly a T
cell phenomenon. This is in accord with
similar observations of Wybran et al.
(1974) in melanoma patients. It is not
a general phenomenon, as indicated by
O'Toole et al.'s (1974) report of pre-
dominantly non-T cell cytotoxicity in
urinary bladder carcinoma. Indeed, we
ourselves have evidence (Nairn et al.,
1975) of change of killer cell type in
our in vitro test applied serially to a
case of melanoma as tumour growth
progressed. Similar findings in murine
tumours are reported by Lamon et at.
(1973).
The effects of serum factors and
antigens on lymphocyte anti-tumour im-
munoreactivity in man have been reported
by Baldwin, Embleton and Price (1973)
and Hellstrom et al. (1973). Our study
in a large series of colonic carcinoma
patients of the influence of serum factors
on the apparent predominantly T lympho-
cyte cytotoxicity has shown inhibition
by 21 % of sera from autochthonous
cytotoxic positive cases (i.e. 7% of all
112 colon carcinoma cases tested). The
normal control lymphocytes obtained
from 20 normal individuals were cytotoxic
by our technique in only 2 of the 112
tests performed. In these 2 tests, lym-
phocytesfrom 2individuals on oneoccasion
each showed 40% and 43% cytotoxicity
compared with a blank reading without
lymphocytes added.
The inhibitory effects were associated
with factors operating on the effector
lymphocytes and on the target tumour
Lymphocytes*
Case no.
1
1
6
6
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cells. Preincubation of reactive lympho-
cytes either with serum or the tumour
antigen extract inhibited cytotoxicity in
most colonic carcinoma cases tested.
Thus, it would seem that lymphocytes
sensitized to tumour antigens are able
to bind soluble antigenic material, thereby
becoming unreactive to the target tumour
cell surface. Serum inhibited both the
lymphocytes and target cells suggesting
the presence of antigen-antibody com-
plexes at or near equivalence. Greater
avidity of lymphocyte surface receptors
for antigen could result in binding of
the complex to the lymphocyte by disso-
ciation of lower avidity antibody in the
complex. Similarly, antibody in the com-
plex might be expected to have greater
affinity for antigen on tumour cells and
result in cross-linking of complex on the
tumour cell surface. Combination of
serum and the antigen extract consistently
showed no blocking when preincubated
with tumour cells, presumably because
of interference by a high concentration
of soluble tumour antigen. However,
preincubation of lymphocytes with serum
and antigen together sometimes had
different effects from either component
alone.
Serum abrogation of the in vitro
cytotoxicity in our tests appears to be
tumour determined because there was no
cross-reaction with unlike carcinomata.
The specificity of inhibitory tumour anti-
gen is in contrast with the observations
of Dickinson et al. (1973); they found
with the macrophage electrophoretic mo-
bility (MEM) test that antigen material
prepared by the same method cross-
reacted with all tumour types. The
difference may be attributable to the
lymphocyte cytotoxicity being a function-
al effector test, possibly less sensitive but
more specific than MEM, which is a
reactor response perhaps capable of being
provoked by a broader spectrum of
antigens. The tumour type specificity
does not support nonspecific explanations
of inactivation in vivo. The apparent
quantitative inhibition by antigen of the
effector cells is consistent with the view
that progressive growth of tumour, by
increasing concentration ofsoluble tumour
antigen in the circulation and acting
either alone or complexed with antibody,
can impair the effector responsiveness in
vivo of anti-tumour lymphocytes.
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